United States FDA approves device that can ‘detect autism’

The FDA have approved the Cognoa device that can help determine autism in some cases
The United States FDA have approved the Cognoa device that can determine autism in children, potentially allowing for speedier diagnosis rates. Photo: Freepik

United States regulators have approved a ‘first-of-its-kind’ to help doctors determine autism in children much sooner, potentially allowing for speedier diagnosis rates.

The US department of Food & Drug Administration (FDA) gave the green light for the Cognoa ASD Diagnosis Aid kit to be marketed.

The machine uses learning-based algorithms to analyse data submitted by parents and health care providers, to determine a positive or negative result for autism.

The designers of the device say it is the first of its kind to be authorized for use for helping to detect autism in the United States.

The Center for Disease Control and Prevention (CDC) says that the average age for an autism diagnosis is older four years old, but Cognoa hopes that this device will bring waiting lists down.

Currently, families having to wait to see a skilled clinician in autism to be assessed for autism.

The Cognoa aid is intended to aid primary care physicians with less specialized training, but can a machine learning device reliably improve the rates of autism diagnosis?

Dr. Jeff Schuren, Director of the FDA Center for Devices & Radiological Health claimed, “Autism spectrum disorder can delay a child’s physical, cognitive and social development, including motor skill development, learning, communication and interacting with others.

The earlier ASD can be diagnosed, the more quickly intervention strategies and appropriate therapies can begin.

“Today’s marketing authorization provides a new tool for helping diagnose”.

A study for the Cognoa ASD Diagnosis Kit involved 425 children between the ages of 18 months and five years, with the device returning results for about a third of the children. Of those who were confirmed negative for autism, a panel of clinical experts agreed with 98% of results detected by the Cognoa aid.

The FDA has cleared the aid to be used on children between 18 months and five years, who are considered most “at risk” to developmental delay. Concerns can be raised either by the parent, caregiver of health provider.

The Cognoa aid kit is not designed to be a standalone diagnostic device, but used in addition to existing diagnostic methods.

Cognoa expects to be making the diagnostic aid device available later this year.

Exit mobile version